#China #Chengdu #Keymed Biosciences #CMG901 #Kang Yue Da

Keymed Biosciences Shows Strong 2025 Interim Progress

Keymed Biosciences Inc. (stock code: 02162.HK) has unveiled impressive interim results for the year 2025, marked by accelerated commercialization and robust research and development (R&D) efforts. These successes are primarily attributed to the company's flagship product, Stapokibart, a monoclonal antibody targeting IL-4Rα, marketed under the name Kang Yue Da.

Financial Highlights

In terms of financial performance, Keymed reported record revenues, drawing attention to a net revenue of approximately 170 million RMB directly linked to the success of Stapokibart. This impressive figure underscores the product's market acceptance and therapeutic effectiveness. Additionally, Keymed's financial health has been reinforced following a successful fundraising round, which generated approximately 864 million HKD, ensuring there are ample resources available to further develop and market their pipeline of drugs effective for various conditions.

Advancements in the R&D Pipeline

Keymed's R&D pipeline is a cornerstone of its future growth strategy. The company has made substantial advancements, particularly with Stapokibart, expanding its indications beyond adult atopic dermatitis (AD) to include chronic rhinosinusitis with nasal polyps (CRSwNP) and seasonal allergic rhinitis (SAR). Currently, Phase III clinical trials are underway for pediatric AD and prurigo nodularis, which are expected to widen the therapeutic reach of their flagship product.

In 2023, AstraZeneca AB acquired an exclusive global license for their asset CMG901, also known as AZD0901, making strides in global Phase II/III trials for cancers including gastric, pancreatic, and biliary tract. Moreover, CM512, a bispecific antibody targeting TSLP and IL-13, is currently undergoing Phase II studies for AD and chronic rhinosinusitis, showing exciting promise.

Academic Recognition

The academic credibility of Keymed has also been significantly bolstered with numerous publications in esteemed journals including The New England Journal of Medicine, Nature Medicine, and JAMA. These publications underscore the clinical relevance of staple treatments like Stapokibart, which has recently been incorporated into Chinese treatment guidelines, marking a pivotal moment in the company's journey.

Strategic Positioning for the Future

Keymed's solid cash reserves, strategic funding endeavors, and differentiated clinical pipeline position the company favorably for competitively priced, high-quality, and innovative therapies for patients both in China and globally. As they continue to navigate the complexities of the biotech industry, Keymed's focus remains on bringing meaningful advancements in treatment options to patients in need.

In summary, with strong interim results, an expanding product portfolio, and significant academic endorsements, Keymed Biosciences is poised to make a mark in the biotechnology landscape and offer improved therapeutic options for various medical conditions.